Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Risk of Urothelial Cancers”

64 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 64 results

Testing effectiveness (Phase 2)Looking for participantsNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Testing effectiveness (Phase 2)Ended earlyNCT01042795
What this trial is testing

Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

Who this might be right for
Urothelial CarcinomaBladder Cancer
University of Michigan 7
Large-scale testing (Phase 3)Not Yet RecruitingNCT07207824
What this trial is testing

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNMIBC
Fudan University 182
Large-scale testing (Phase 3)WithdrawnNCT07313891
What this trial is testing

Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Bladder (Urothelial, Transitional Cell) CancerUrothelial Carcinoma Bladder+1 more
Relmada Therapeutics, Inc.
Large-scale testing (Phase 3)Ended earlyNCT02450331
What this trial is testing

Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

Who this might be right for
Carcinoma, Transitional Cell
Hoffmann-La Roche 809
Large-scale testing (Phase 3)Study completedNCT05136898
What this trial is testing

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
UroGen Pharma Ltd. 8
Not applicableLooking for participantsNCT07321210
What this trial is testing

Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC): A Randomized Clinical Trial

Who this might be right for
Upper Tract Urothelial CarcinomaLymph Node Dissection
Tianjin Medical University Second Hospital 150
Post-approval studies (Phase 4)Active Not RecruitingNCT04701151
What this trial is testing

NORTH-REG Dwell-Time Study

Who this might be right for
Side Effect of Drug
Jørgen Bjerggaard Jensen 314
Not applicableLooking for participantsNCT06120387
What this trial is testing

Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer

Who this might be right for
Locally AdvancedUrothelial Carcinoma Ureter
Xuesong Li 90
Testing effectiveness (Phase 2)Study completedNCT03558503
What this trial is testing

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
UroGen Pharma Ltd. 63
Testing effectiveness (Phase 2)Study completedNCT03914794
What this trial is testing

Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Who this might be right for
Bladder CancerNMIBCNon-Muscle Invasive Bladder Cancer+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 30
Not applicableLooking for participantsNCT05080998
What this trial is testing

Longitudinal Bladder Cancer Study for Tumour Recurrence

Who this might be right for
Urothelial Bladder Cancer
Pacific Edge Limited 450
Early research (Phase 1)Study completedNCT02808143
What this trial is testing

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Recurrent Bladder CarcinomaStage 0a Bladder Urothelial CarcinomaStage 0is Bladder Urothelial Carcinoma+1 more
Northwestern University 9
Early research (Phase 1)Study completedNCT03053635
What this trial is testing

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Theralase® Technologies Inc. 6
Testing effectiveness (Phase 2)Ended earlyNCT04294277
What this trial is testing

Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery

Who this might be right for
Urothelial Cancer
European Association of Urology Research Foundation 2
Not applicableUnknownNCT04943380
What this trial is testing

Efficacy and Utility of Cxbladder Tests in Hematuria Patients

Who this might be right for
HematuriaUrothelial Carcinoma
Pacific Edge Limited 684
Early research (Phase 1)Looking for participantsNCT05843448
What this trial is testing

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Who this might be right for
High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
University of California, Davis 30
Not applicableLooking for participantsNCT05646485
What this trial is testing

Bladder Cancer Screening Trial

Who this might be right for
Bladder CancerUrothelial CarcinomaHematuria+1 more
University of Texas Southwestern Medical Center 1,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT03504163
What this trial is testing

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

Who this might be right for
Bladder Cancer
Memorial Sloan Kettering Cancer Center 45
Testing effectiveness (Phase 2)Study completedNCT04311580
What this trial is testing

Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure

Who this might be right for
Bladder Cancer
University of Rome Tor Vergata 52
Load More Results